T he release of cytoplasmic microparticles (membrane covered cytoplasmic particles) from different cell types under physiological conditions has been well described. During the maturation of erythroid cells, such particles are generated and contribute to the elimination of transferrin receptors. Such physiological processes are reminiscent of the production of platelets. In recent years, the in vitro production of endothelial cell microparticles has been demonstrated and the mechanism of generation of these particles has been elucidated. 1 Microparticles developing as a result of endothelial cell activation differ from particles that are generated as a consequence of apoptotic processes. 2 
MATERIALS AND METHODS
An index case of Burkitt's leukaemia and Epstein-Barr virus (EBV) transformed normal B cells were studied prospectively. List mode analysis of 225 cases of acute leukaemia or lymphoma with previously performed immune phenotyping as part of an institutional review board approved study was also carried out.
Bone marrow cells were separated on Ficoll and any remaining red blood cells lysed. Immune phenotypic staining of these cells, in addition to lymph node and tissue culture suspension cells, was performed according to previously published methods. 3 4 Briefly, mononuclear cells were resuspended in phosphate buffered saline (PBS) containing 30% adult bovine serum (to block Fc receptors) and stained at room temperature for 30 minutes using the antibody concentrations recommended by the manufacturers. After staining, samples were washed with PBS and resuspended in PBS + 0.5% formaldehyde before flow cytometric analysis. Events were collected on the immature blast population using forward scatter (FS)/side scatter (SS) analysis as inferred from initial SS/CD45 analysis. There was a second group of events recognised with the platelet or erythrocyte population on FS/SS histograms, so these populations were analysed separately, and were shown to include leukaemia/ lymphoma cell microparticles. The antibody panel included antibodies to: CD45, CD19, CD10, CD20, CD38, HLA-DR, surface IgG, l chain, k chain, CD2, CD3, CD4, CD5, CD7, CD8, CD11, CD13, CD33, CD34, CD41, and glycophorin A, in addition to CD32, CD21, CD49d, CD80, and CD86 in the index case and the EBV transformed normal B cells. The presence of apoptotic bodies was investigated using annexin V (AnnV)-propidium iodide (PI) colabelling by flow cytometry. 5 Two colour histograms of the leukaemia/lymphoma cell microparticle gated populations were analysed. The AnnV negative (2)/PI negative (2) population represents viable cells, the AnnV+/PI2 population represents early apoptotic cells, and the AnnV+/PI+ population represents late apoptotic or dead cells.
Density centrifugation of the bone marrow specimen to isolate cellular microparticles was carried out using a published method, with slight modifications. 1 Briefly, the bone marrow specimen in sodium citrate was spun down at 160 6g for 10 minutes using an IEC PR-6000 centrifuge to obtain platelet rich plasma. The upper layer of platelet rich plasma was spun down at 1500 6g for six minutes to obtain platelet poor plasma. The platelet poor plasma was stained with combinations of conjugated CD42a, glycophorin A, CD20, and P1H12 in the dark on a shaker for 20 minutes and run on an EPICS-XL flow cytometer. Gating was based on the isotype control staining patterns.
RESULTS
Microparticles were present in abundance in the bone marrow of the index case at the time of diagnosis. The patient was a child with acute lymphoblastic leukaemia (ALL) with L3 morphology (Burkitt's type) according to the French-American-British (FAB) classification and a mature B cell neoplasm according to the World Health Organisation classification. EBV late membrane protein-1 was demonstrated in the tumour cells. The small blue cellular particles were recognised as microparticles because of the multiple cytoplasmic vacuoles characteristic of L3 morphology on the Wright/Giemsa stained bone marrow aspiration smears under light microscopy ( fig 1) .
Flow cytometric immune phenotyping of bone marrow cells revealed a small population of events with FS and SS characteristics of the platelet or erythrocyte population on FS/ SS histograms. The staining pattern of this population was the same as, but less intense (because of the small size) than, the leukaemia population, revealing high CD19, CD10, l chain, CD38, and DR expression; in addition, this population was negative for platelet and erythrocyte associated markers, such as CD41 and glycophorin A, respectively (fig 2) . Density centrifugation isolated microparticles revealed a population of events positive for CD20, along with other smaller populations consistent with platelets and erythrocytes (fig 2) .
These microparticles did not appear to be a result of the apoptotic process for the following reasons: (a) there were very few apoptotic figures identifiable on the Wright/Giemsa stained bone marrow aspiration smears ( fig 1) ; (b) leukaemia/lymphoma cell microparticles contained vacuoles, as did the intact leukaemic blasts, and there were no morphological signs of apoptosis, consistent with direct release; and (c) many of the particles were negative for AnnV and PI, characteristics of apoptosis. Furthermore, the particles also partially expressed adhesion and costimulatory molecules including CD32, CD21, CD49d, CD80, and CD86, as did the leukaemic clone. Flow cytometric analysis of EBV transformed B cells from a subject without a malignant disorder revealed leukaemia/lymphoma cell microparticles with similar characteristics to the case discussed above including CD32, CD21, CD49d, CD80, and CD86 expression.
A review of flow cytometric immune phenotyping results performed previously on three patients with mature B cell ALL and lymph node samples on two patients with Burkitt's lymphoma revealed a similar population, with staining patterns similar to the malignant clone. Upon further review of the results on leukaemia samples at our institution (220 cases), one acute myeloid leukaemia (AML)-M7 and four B precursor ALL cases were found to have identifiable potential leukaemia/lymphoma cell microparticle populations. List mode analysis of that population (leukaemia/lymphoma cell microparticle gate) revealed small percentages of microparticles sharing the characteristics of the leukaemic clone.
DISCUSSION
The generation of leukaemia/lymphoma cell microparticles may not be a rare phenomenon in childhood leukaemias and it appears to be substantially more pronounced in mature B cell tumours than in precursor B cell neoplasms. The degree of leukaemia/lymphoma cell microparticle production may be related to the cellular activation status, as shown by costimulatory molecule expression, or may just be a reflection of the characteristics of the leukaemia type and/or the cell type that the leukaemia has originated from, such as increased mechanical fragility. This last notion is consistent with the known rapid tumour cytolysis seen during chemotherapy in mature B cell neoplasms. The generation of such particles was reported in an AML-M7 cell line in vitro. 6 Despite reviewing more than 20 cases of AML-M7 bone marrow immune phenotyping results, we identified only one clearcut case with a leukaemia/lymphoma cell microparticle population. This could partially be attributed to loss of particles through mononuclear cell isolation techniques that are not designed specifically to enrich low density particles, and it may be more common than we have detected. Nevertheless, observing leukaemia/lymphoma cell microparticle generation in AML-M7 cases may be a reflection of megakaryocyte biology, namely platelet production.
''Are there any implications for the presence of leukaemia/lymphoma cell microparticles in leukaemia or lymphoma?''
It is important to be aware of this phenomenon and not to confuse leukaemia/lymphoma cell microparticles with platelets. More importantly, are there any implications for the presence of leukaemia/lymphoma cell microparticles in leukaemia or lymphoma? Increased numbers of endothelial cell microparticles were isolated from the blood of patients with systemic lupus erythematosus compared with healthy individuals. 7 In addition, it has been postulated that microparticles can contribute to thrombotic disorders. 7 8 Apoptotic bodies originating from human immunodeficiency virus infected T cells have been shown to transfer the virus into other cells. 9 However, because leukaemia/lymphoma cell microparticles are not apoptotic bodies, they may not be good targets for cellular uptake but, rather, may circulate in the blood and lymph vessels. Further investigations are needed to determine whether leukaemia/lymphoma cell microparticle generation is related to cellular activation associated with EBV infection, with potential clinical consequences.
